June 02, 2025 a 03:43 pm
ABBV: Fundamental Ratio Analysis - AbbVie Inc.
AbbVie Inc., a key player in the pharmaceutical industry, offers a range of therapies addressing various diseases. With a robust product portfolio, AbbVie holds a significant presence in the drug market. Investors may find value in AbbVie's consistent product innovation and strategic collaborations.
Fundamental Rating
AbbVie has a solid fundamental rating with an overall score of 3 indicating stable financial health. Below is a detailed breakdown of their scores:
| Category | Score | |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return on Equity | 5 | |
| Return on Assets | 4 | |
| Debt to Equity | 1 | |
| Price to Earnings | 1 | |
| Price to Book | 1 |
Historical Rating
AbbVie's historical ratings provide insights into its performance over time. Notable recent scores are listed below:
| Date | Overall Score | DCF | ROE | ROA | Debt to Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-05-30 | 3 | 5 | 5 | 4 | 1 | 1 | 1 |
| Historical | 0 | 5 | 5 | 4 | 1 | 1 | 1 |
Analyst Price Targets
Analysts maintain positive sentiment towards AbbVie with a consensus price target reflecting potential for growth:
| High | Low | Median | Consensus |
|---|---|---|---|
| 220 | 215 | 217.5 | 217.5 |
This chart represents the historical stock price movement of AbbVie.
Analyst Sentiment
Analyst recommendations depict a strong buy consensus, signaling investor confidence:
| Recommendation | Count | Distribution |
|---|---|---|
| Buy | 25 | |
| Hold | 12 |
Conclusion
AbbVie Inc. remains a strong contender in the pharmaceutical sector, with solid fundamental scores and a favorable analyst outlook. The company's diverse product portfolio and strategic drug development collaborations support growth prospects. Potential investors should weigh the high buy sentiment against financial ratios and market competition. Overall, AbbVie presents both opportunities and risks linked to market dynamics and industry regulation.